je.st
news
Tag: demonstrate
Axalta Exhibits Energy Solutions Portfolio at CWIEME to Demonstrate 150 Years of Innovation
2016-06-30 16:53:00| Coatings World Breaking News
Tags: years
solutions
energy
portfolio
WABCO and ZF demonstrate prototype of Evasive Maneuver Assist for commercial vehicles; connecting active braking and steering capability
2016-06-30 12:55:59| Green Car Congress
Tags: active
commercial
assist
vehicles
Ceres Power to demonstrate SOFC stack technology for EV range extender with Nissan; light commercial vehicle
2016-06-28 17:55:57| Green Car Congress
Tags: power
range
technology
light
DOE selects 2 projects to demonstrate feasibility of enhanced water recovery; producing usable water from CO2 storage sites
2016-06-05 13:56:33| Green Car Congress
Tags: sites
water
projects
storage
New Data Evaluating KEYTRUDA (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent
2016-06-04 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Based on Initial Results Presented at 2016 ASCO Annual Meeting, Merck Has Initiated Two Phase 3 Studies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from an initial proof-of-concept study of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, combined with standard treatments, one with bevacizumab and others without, in non-small cell lung cancer (NSCLC) including chemotherapy in previously untreated patients with NSCLC; the study showed overall response rates (ORR) ranging from 48 to 71 percent, depending on the therapy used. Language: English Contact: MerckMedia Contacts:Pamela Eisele, (267) 305-3558orCourtney Ronaldo, (908) 236-1108orInvestor Contacts:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] next »